Radar›Companies›Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 9
United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 9

A five-company surgical and medical instruments and apparatus cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderDarioHealth · 49
Strongest available pathSensus Healthcare · -5.3%
Widest latest marginNephros · 6.4%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DRIO · Nasdaq

DarioHealth

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2011New York City$66.3M market cap
View full Companies Radar profile
49Cautious
Snapshot price$6.77as of page date
Monthly-close return-97.5%five-year window
FY2025 revenue$0.02BDarioHealth Corp.
Net margin-186.6%FY2025
P/E snapshot-6.0xone ratio, not a verdict
Prism attention37.6%share across these five
Filing track recordRevenue, USD billions
+9.0%
$0$0.0B$0.0B$0.0BFY2021: $0.021BFY2022: $0.028BFY2023: $0.020BFY2024: $0.027BFY2025: $0.022B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.2%
52-week position8% through range
$5.84$17.74
News mentions939
Community mentions0partial coverage
U.S.-scope patents0
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position23/100
Capital-event signal81/100
Innovation pulse27/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 10 M&A involvements, 2 asset-acquisition events and 34 contract events.

Innovation activity

Prism records 6 lifetime product-launch events, 1 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2NEPH · Nasdaq

Nephros

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1997River Edge, New Jersey$49.4M market cap
View full Companies Radar profile
49Cautious
Snapshot price$4.55as of page date
Monthly-close return-47.5%five-year window
FY2025 revenue$0.02BNEPHROS INC
Net margin6.4%FY2025
P/E snapshot28.4xone ratio, not a verdict
Prism attention16.0%share across these five
Filing track recordRevenue, USD billions
+81.8%
$0$0.0B$0.0B$0.0BFY2019: $0.010BFY2020: $0.009BFY2021: $0.010BFY2024: $0.014BFY2025: $0.019B20192020202120242025
FY2019–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 16.1%
52-week position50% through range
$2.66$6.42
News mentions400
Community mentions0partial coverage
U.S.-scope patents163
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal62/100
Management stability90/100
Market position6/100
Capital-event signal67/100
Innovation pulse7/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 3 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3BTCY · OTC

Biotricity

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2015Marion, Ohio$2.5M market cap
View full Companies Radar profile
46Cautious
Snapshot price$0.12as of page date
Monthly-close return-99.4%five-year window
FY2025 revenue$0.01BBIOTRICITY INC.
Net margin-61.1%FY2025
Prism attention17.7%share across these five
Filing track recordRevenue, USD billions
+307.4%
$0$0.0B$0.0B$0.0BFY2021: $0.003BFY2022: $0.008BFY2023: $0.010BFY2024: $0.012BFY2025: $0.014B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 42.1%
52-week position5% through range
$0.09$0.75
News mentions441
Community mentions0partial coverage
U.S.-scope patents3
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal54/100
Management stability90/100
Market position0/100
Capital-event signal69/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 5 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4SRTS · Nasdaq

Sensus Healthcare

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2010Boca Raton, Florida$57.9M market cap
View full Companies Radar profile
37Cautious
Snapshot price$3.52as of page date
Monthly-close return-5.3%five-year window
FY2025 revenue$0.03BSensus Healthcare, Inc.
Net margin-28.1%FY2025
P/E snapshot-20.3xone ratio, not a verdict
Prism attention19.2%share across these five
Filing track recordRevenue, USD billions
-34.3%
$0$0.0B$0.0B$0.0BFY2024: $0.042BFY2025: $0.027B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -34.3%
52-week position30% through range
$2.66$5.49
News mentions479
Community mentions0partial coverage
U.S.-scope patents61
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal24/100
Management stability90/100
Market position3/100
Capital-event signal72/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5ALUR · OTC

Allurion

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2009Wellesley, Massachusetts$1.5M market cap
View full Companies Radar profile
36Cautious
Snapshot price$1.45as of page date
Monthly-close return-99.4%five-year window
FY2025 revenue$0.01BALLURION TECHNOLOGIES, INC.
Net margin-188.8%FY2025
Prism attention9.5%share across these five
Filing track recordRevenue, USD billions
-71.5%
$0$0.0B$0.0B$0.1BFY2023: $0.053BFY2024: $0.032BFY2025: $0.015B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -46.6%
52-week position15% through range
$0.23$8.52
News mentions237
Community mentions16partial coverage
U.S.-scope patents128
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position7/100
Capital-event signal50/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Sensus Healthcare
-5.3%
Nephros
-47.5%
DarioHealth
-97.5%
Biotricity
-99.4%
Allurion
-99.4%

Latest revenue

USD billions, official filing scope shown on each company card.

Sensus Healthcare
$0.03B
DarioHealth
$0.02B
Nephros
$0.02B
Allurion
$0.01B
Biotricity
$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Nephros
6.4%
Sensus Healthcare
-28.1%
Biotricity
-61.1%
DarioHealth
-186.6%
Allurion
-188.8%

Prism news attention

Normalized share across these five names; attention is not quality.

DarioHealth
37.6%
Sensus Healthcare
19.2%
Biotricity
17.7%
Nephros
16.0%
Allurion
9.5%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

DarioHealth leads the conversation

It holds 37.6% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $0.02B.

Price path

Sensus Healthcare leads the available price paths

Its monthly-close return is -5.3% for the five-year window. At the other end, Allurion is -99.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Nephros has the widest latest margin

Its FY2025 net margin is 6.4%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Sensus Healthcare shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -20.3x while its five-year window price return is -5.3%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DRIO

DarioHealth

939available Prism news records

Prism top themes

Price action & investor response
39
Earnings & financial performance
38
Capital allocation & transactions
7
Leadership & governance
7
Legal, arbitration & regulatory
3

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-28.6%75 latest 12m vs 105 prior 12m
2023-12: 0 mentions2024-01: 6 mentions2024-02: 16 mentions2024-03: 19 mentions2024-04: 7 mentions2024-05: 10 mentions2024-06: 10 mentions2024-07: 5 mentions2024-08: 6 mentions2024-09: 2 mentions2024-10: 14 mentions2024-11: 10 mentions2024-12: 1 mentions2025-01: 16 mentions2025-02: 8 mentions2025-03: 15 mentions2025-04: 11 mentions2025-05: 7 mentions2025-06: 2 mentions2025-07: 4 mentions2025-08: 4 mentions2025-09: 8 mentions2025-10: 5 mentions2025-11: 4 mentions2025-12: 4 mentions2026-01: 4 mentions2026-02: 4 mentions2026-03: 9 mentions2026-04: 14 mentions2026-05: 13 mentions2023-122026-05

Machine-classified coverage tone

89.4% positive-5.3 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 9stock performance 9digital health consultation 8earnings report 8preventive health initiative 7lifestyle medicine 6investor conference 5pharma digital strategy 4

Keyword tag occurrences in available Prism news records.

Coverage: 2015-12-31–2026-05-16 · trend and themes shown through 2026-05
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DRIO

DarioHealth

through 2026-05-04
Earnings releases 32Business contracts 9Leadership changes 8M&A 5Company announcements 1
  1. Earnings releases

    DarioHealth Corp. announced today that it will release its financial results for the 1st quarter ended March 31 st , 2026

  2. Leadership changes

    today announced the appointment of John R. Palumbo to its Board of Directors.

  3. Business contracts

    We entered into sales agreement, dated March 30, 2026 (the “Sales Agreement”), with A.G.P./Alliance Global Partners (“A.G.P.” or the “Agent”), relating to shares of our common stock.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NEPH

Nephros

through 2026-04-16
Earnings releases 23Leadership changes 8Company announcements 3Asset acquisitions 1
  1. Leadership changes

    Nephros Inc., a water technology company providing filtration solutions to medical and commercial markets, announced an expansion of its strategic focus in the Greater New York City region with the addition of Dana Cunningham as a dedicated regional sales leader.

  2. Earnings releases

    Full-year net revenue increased 33% year-over-year to $18.8 million, while fourth-quarter revenue rose 22% to $4.7 million.

  3. Company announcements

    Nephros Inc., a water technology company providing filtration solutions to medical and commercial markets, announced its entry into the Puerto Rican market on February 13, 2026.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BTCY

Biotricity

through 2026-02-11
Earnings releases 36Company announcements 10Regulatory 2Business contracts 1
  1. Earnings releases

    Q3-FY26 Financial Highlights Revenue increased 10.2% to $4 million from $3.6 million in the corresponding prior year period.

  2. Regulatory

    the popularity of their FDA-cleared cardiac monitoring devices, particularly the next-gen Biocore Pro.

  3. Company announcements

    Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its accelerated timeline to achieving EBITDA positive. The company now expects to reach this significant milestone before the end of calendar 2024, earlier than previously anticipated.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SRTS

Sensus Healthcare

through 2026-02-17
Earnings releases 23Leadership changes 7
  1. Earnings releases

    Sensus Healthcare reports Q4 EPS (19c) vs. 9c last year

  2. Leadership changes

    Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately.

  3. Earnings releases

    Revenues for the fourth quarter of 2025 were $4.9 million, compared with $13.1 million for the fourth quarter of 2024. Net loss for the fourth quarter of 2025 was $3.2 million, or $0.19 per share.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ALUR

Allurion

through 2026-01-12
Earnings releases 15Leadership changes 7Company announcements 3M&A 3Business contracts 2
  1. Earnings releases

    Fourth quarter revenue of $3.3 million to $3.7 million , a 22% to 37% increase quarter-over-quarter, and full-year revenue of approximately $15 million

  2. Regulatory

    declared effective by the SEC on December 20, 2024

  3. Leadership changes

    Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence
2019 extracted base$10.20B–$11.75B
2025 extracted forecast$11.50B–$21.52B
Implied source CAGR7.4%
increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records
Latest 12m volume+8.7%36648 vs 33721 records
Positive classified tone66.7%+5.2 pp vs prior four quarters
2024-01: 2,862 mentions2024-02: 2,508 mentions2024-03: 2,665 mentions2024-04: 2,848 mentions2024-05: 2,984 mentions2024-06: 2,155 mentions2024-07: 2,123 mentions2024-08: 2,108 mentions2024-09: 2,116 mentions2024-10: 2,483 mentions2024-11: 2,604 mentions2024-12: 2,045 mentions2025-01: 2,853 mentions2025-02: 5,160 mentions2025-03: 3,909 mentions2025-04: 3,553 mentions2025-05: 2,612 mentions2025-06: 1,780 mentions2025-07: 3,188 mentions2025-08: 7,906 mentions2025-09: 2,642 mentions2025-10: 2,462 mentions2025-11: 2,103 mentions2025-12: 2,450 mentions2026-01: 1,736 mentions2026-02: 4,268 mentions2026-03: 3,588 mentions2026-04: 4,213 mentions2026-05: 312 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates
7,802
medical drama series
7,076
cannabis legalization trends & economic impact
6,207
recreational marijuana usage
5,579
in-flight medical emergency protocols
4,688
medical marijuana laws & regulatory frameworks
3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 41–48. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Sensus Healthcare has the widest attention-readiness rank gap

It ranks #2 by measured news attention (19.2%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Sensus Healthcare in Companies Radar

Biotricity shows a price-operating divergence to inspect

Its displayed filing-revenue change is +307.4% while its available monthly-close return is -99.4%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Biotricity in Companies Radar
Explanations

Attention measures coverage volume, not quality

DarioHealth's 37.6% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open DarioHealth in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open DarioHealth's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 49/100 score.

Open DarioHealth in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon